A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Platinum-resistant Ovarian Cancer · Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma · Clear Cell Adenocarcinoma of Ovary · Clear Cell Adenocarcinoma of Vulva · Clear Cell Adenocarcinoma of Vagina · Clear Cell Adenocarcinoma of Cervix · Clear Cell Adenocarcinoma of Uterus · Clear Cell Adenocarcinoma of Fallopian Tube · Clear Cell Adenocarcinoma of Peritoneum · Endometrial Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 80 (planned)
- Started
- May 1, 2025
- Main results expected
- Jul 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator
Measured over: Throughout the study up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06730347 · record last updated 2026-06-02 · checked 2026-11-09 15:47 UTC